drugset / Trial / NCT06562738

Clinical Study on Efficacy and Safety of Hetrombopag in the Preoperative Patients of Thrombocytopenia

NCT06562738

NaSingle-groupOpen-labelTreatment

Summary

This is an investigator-initiated, single-arm, prospective clinical study to evaluate the efficacy and safety of heptapopal in the treatment of thrombocytopenia prior to elective surgery

Timeline

Start
2024-06-01
Primary completion
2025-01-31
Completion
2025-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Hetrombopag Small molecule 7.5 mg Oral

Indications